null

null

null

null

null

null

null

null

null

null

null

null

null

null

null

null

null

null

0.76x Total Debt / Equity (Moderate leverage)

A 200bps rate increase raises annual interest expense ~$150-200M on ~$20B long-term debt; manageable given ~$6B operating cash flow but compresses free cash flow margin by ~3%

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

Elevance is a domestic US health insurer; no material geopolitical supply chain chokepoints — primary dependency is domestic pharmacy benefit supply (PBM/drug distribution), not geopolitical

Elevance derives ~98% of revenue domestically; international revenue is negligible, so sovereign currency devaluation exposure is effectively null

Predominantly US-only operator across 14+ Blue Cross Blue Shield licensed states; no material international revenue footprint, currency devaluation risk is de minimis

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

CareMore/Ingenio Rx (captive PBM) and Epic/pharmacy data platforms represent significant operational inputs; no single vendor exceeds 30% of total cost but PBM concentration is notable

Managed care / health insurance — B2B and B2C premium-based model; cloud disruption would impair claims processing and digital health platforms but core insurance contracts remain intact for 30-90 days

Healthcare services and pharmacy benefit management (Carelon/Ingenio Rx); cloud termination would disrupt analytics and digital health delivery but not immediately terminate member coverage obligations

Moderate-to-low API coupling risk; Elevance uses internal platforms (Carelon) plus third-party integrations; proprietary claims adjudication systems create switching friction but no dominant single API dependency

Fails Howey Test — premium revenue model is a regulated insurance contract, not an investment of money in a common enterprise with profit expectation; Howey risk is null

Very High

CCPA exposure is significant given millions of California members; GDPR exposure is minimal due to negligible EU operations; HIPAA is the dominant compliance framework, adding regulatory overhead

High — DOJ/FTC scrutiny on BCBS market allocation agreements and insurer consolidation; 2022 BCBS antitrust settlement (~$2.7B) signals ongoing exposure; market dominance in state-level Blue franchises under watch

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

~90%+ recurring — multi-year employer group contracts, government (Medicaid/Medicare) contracts, and individual ACA plans; transactional revenue (fee-for-service) is a small minority

Premium-based recurring revenue (~$156B FY2023 revenue); secondary monetization via Carelon health services fees and pharmacy benefit spreads

Actuarially-based annual premium repricing; medical loss ratio (MLR) floors (85% large group, 80% individual) constrain margin; pricing power exists at renewal but is regulated and competitively contested

Moderate — annual premium increases of 5-10% achievable in employer markets; government programs (Medicaid/Medicare) face rate-setting by CMS/states, limiting unilateral pricing power

Gross margin ~15-18% (after medical costs); operating margin ~5-7%; health insurance MLR of ~85-87% structurally caps gross margin relative to non-insurance businesses

Low free-rider risk; health insurance requires premium payment for coverage; adverse selection is a concern but not free-riding; employer group retention rates typically exceed 85-90%

Revenue growth is sublinear to headcount; claims processing automation and digital health platforms allow scale; doubling revenue would require ~30-40% headcount increase, not doubling

Marginal cost of adding members is driven by medical costs (variable) not headcount; administrative cost ratio declines at scale; Carelon services unit has higher fixed-cost leverage

BCBS licensee structure creates compliance drift risk across 35+ independent plans; Elevance operates 14 states under BCBS license with shared brand standards; inter-plan disputes and audit risks are ongoing

At 10x scale, CAC economics improve via broker channel leverage and employer RFP scale; however, regulatory capital requirements and MLR constraints would intensify; current CAC estimated at $300-600 per member

Weak direct network effects; larger membership improves provider contracting leverage (indirect effect); no classic platform network effect — value does not compound with user growth the way digital platforms do

5.5% Return on Assets (Excellent)

Tier 2 — highly recession-resistant; Medicaid enrollment counter-cyclically increases in downturns; employer-sponsored insurance dips with unemployment but government programs offset; essential healthcare spending is inelastic

Employer-sponsored group health plan members (~40% of revenue); concentrated among large national employers with multi-year ASO or fully-insured contracts

Government program beneficiaries — Medicaid managed care and Medicare Advantage (~35-40% of revenue); concentration risk in CMS and state Medicaid agency contract renewals

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

0.6% CapEx / Revenue (Low-CapEx Asset-Light)

0001156039

ELV